摘要
目的探讨糖类抗原125(CA125)阴性卵巢癌患者血清人附睾蛋白4(HE4)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)表达水平及与患者预后的关系。方法选取107例CA125阴性卵巢癌患者作为观察组,81例良性卵巢肿瘤患者作为对照组。比较两组患者HE4、CEA、NSE表达水平;采用多因素Logistic回归模型分析CA125阴性卵巢癌患者预后的影响因素。结果观察组患者血清HE4、CEA、NSE水平均明显高于对照组,差异均有统计学意义(P﹤0.01)。预后良好与预后不良患者分化程度、临床分期及HE4、CEA、NSE水平比较,差异均有统计学意义(P﹤0.01)。多因素Logistic回归分析结果显示,HE4、CEA、NSE高表达均为CA125阴性卵巢癌患者预后不良的危险因素(P﹤0.05)。结论与良性卵巢肿瘤患者相比,HE4、CEA、NSE在CA125阴性卵巢癌患者中呈高表达,HE4、CEA、NSE表达水平能影响CA125阴性卵巢癌患者的预后,三者水平越低,患者预后越好。
Objective To investigate the expression levels of serum human epididymis protein 4(HE4),carcinoembryonic antigen(CEA)and neuron specific enolase(NSE)in carbohydrate antigen 125(CA125)negative ovarian cancer patients and their relationship with prognosis.Method A total of 107 patients with CA125 negative ovarian cancer were selected as observation group and 81 patients with benign ovarian tumor were selected as control group.The expression levels of HE4,CEA and NSE were compared between the two groups.Multivariate Logistic regression model was used to analyze the prognostic factors of CA125 negative ovarian cancer patients.Result The levels of serum HE4,CEA and NSE in observation group were significantly higher than those in control group,the differences were statistically significant(P<0.01).There were significant differences in differentiation degree,clinical stage and HE4,CEA,NSE levels between patients with good prognosis and poor prognosis(P<0.01).Multivariate Logistic regression analysis showed that high expression of HE4,CEA and NSE were risk factors for poor prognosis of CA125 negative ovarian cancer patients(P<0.05).Conclusion Compared with benign ovarian tumor patients,HE4,CEA and NSE are highly expressed in CA125 negative ovarian cancer patients,and the expression levels of HE4,CEA and NSE can affect the prognosis of CA125 negative ovarian cancer patients.The lower the levels of the three indexes,the better the prognosis of ovarian cancer patients.
作者
陈鹏
张冰
廖琳
王峰
CHEN Peng;ZHANG Bing;LIAO Lin;WANG Feng(Department of Clinical Laboratory,the First People’s Hospital of Zhengzhou,Zhengzhou 450000,He’nan,China)
出处
《癌症进展》
2024年第18期2061-2064,共4页
Oncology Progress
关键词
卵巢癌
人附睾蛋白4
癌胚抗原
神经元特异性烯醇化酶
糖类抗原125阴性
预后
ovarian cancer
human epididymis protein 4
carcinoembryonic antigen
neuron specific enolase
carbohydrate antigen 125 negative
prognosis